NCT03169231View on ClinicalTrials.gov

Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Aging Frailty
Interventions
BIOLOGICAL

Longeveron Mesenchymal Stem Cells (LMSCs)

Intravenously delivered

OTHER

Placebo

Intravenously delivered

Trial Locations (7)

33014

Panax Clinical Research, Miami Lakes

33125

Miami VA Healthcare System, Miami

33134

Clinical Research of South Florida, Coral Gables

33176

Vista Health Research, Miami

33180

Soffer Health Institute, Aventura

33912

Clinical Physiology Associates, Fort Myers

34102

Advanced Research for Health Improvement, LLC, Naples

Sponsors

Lead Sponsor

Longeveron Inc.
All Listed Sponsors
lead

Longeveron Inc.

INDUSTRY

NCT03169231 - Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty | Biotech Hunter | Biotech Hunter